Politics Of Mega-Mergers: Health Reform And U.S. Biopharma Realignment
One theme tying together the two mega-mergers announced so far in 2009 is the sense that biopharma companies are taking defensive measures to prepare for health care reform in the U.S
You may also be interested in...
$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.
Jon Leibowitz, a fierce opponent of reverse settlements between brand name and generic companies, is set to head the Federal Trade Commission
Medicaid rebate increase and follow-on biologics could take $70 billion from pharma over 10 years, key staffer says—but industry should be happy with that trade.